VaxigripTetra (Quadrivalent Influenza Vaccine) – evidence for clinical and economic benefits from vaccination in population aged 65 and over in Poland
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2017, Vol 2, Issue 2
Abstract
Background: Vaccination is considered to be the most effective way of preventing influenza related-illnesses and their complications, which is particularly important in elderly population (aged 65+), often characterized with more rapid and severe clinical course of infection. Quadrivalent influenza vaccines (QIV) have been developed to avoid the poor antigenic match observed in the trivalent formulation vaccine (TIV). Methods: The study assess the immunogenicity, cost-effectiveness and impact on the Polish budget of inactivated quadrivalent influenza vaccine (VaxigripTetra), assuming its reimbursement in the active immunization of adults 65 years of age and older. Results: As clinical results have shown, non-inferior immunogenicity of QIV to each TIV for the shared strains and superior immunogenicity of QIV to each TIV for the alternate B strain. The inactivated QIV was well tolerated. VaxigripTetra is a highly cost-effective option compared to the strategy of “no vaccination” (ICUR=14,988 PLN/QALY – payer’s + patients’ perspective [PPP+P], ICUR=6,838 PLN/QALY – payers’ perspective [PPP]) and also to TIV (ICUR=121,418 PLN or ICUR=114,360 PLN, respectively). The increase of the public payer’s expenditures – 9.0-23.3 million PLN annually – will result in additional health effects: 1,091 – 4,805 GP visits, 175-771 hospitalizations and 74-326 deaths avoided per year. Conclusions: VaxigripTetra reimbursement could trigger a faster switch from TIVs to QIVs and at the same time could increase the vaccine coverage of the elderly population in Poland, which would lessen the ILI-related negative impact on that population at a reasonable cost to the healthcare system, while providing some savings to society.
Authors and Affiliations
Łukasz Kaczyński, Dariusz Pawlik, Beata Serafin, Rafał Wójcik, Marcin Kaczor, Joanna Lis, Ewelina Bernaszuk, Katarzyna Wepsięć
Keywords
Related Articles
- EP ID EP326192
- DOI 10.7365/JHPOR.2017.2.3
- Views 53
- Downloads 0
Reimbursement and value assessment frameworks: ensuring patients’ access to asthma medicines in Ukraine
Background. Health technology assessment (HTA) introduction and implementation for development of the National List of Essential Medicines (NLEM) took place in Ukraine in 2016 in the context of National Drug Policy until...
Asthma boundaries in a social security perspective
ntroduction: Patients in Poland, including asthmatics are beneficiaries of social security system in case of severe disease exacerbation. Usually sick leave due to uncontrolled asthma is enough to get better and come bac...
Approach to uncertainty in health technology assessment in a Central and Eastern European country: appraisal of cancer drugs by a Polish HTA agency in presence of high crossover rates in clinical trials
Background: Health technology assessment (HTA) plays an important role in reimbursement decision making in Poland and its principles are similar to those used in other countries. However, specific inter-country differenc...
Assessment of quality of life, disease activity and productivity loss of patients with ulcerative colitis in Poland
Purpose: The aim of the study was to assess the relationship between the disease activity and both indirect costs and health-related quality of life among ulcerative colitis (UC) patients in Poland. Methods: A questionn...
Economic analysis of Noqturina® (oral lyophilisate) use in the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria
Introduction: Nocturia relates to the need to urinate at night when micturition was preceded by sleep and immediately followed by a period of sleep. The aim of this analysis is to examine the cost-effectiveness of desmo...